Patent Settlements May Break EU Law
UK’s Paroxetine Referral Raises Competition Issues
Patent-litigation settlements reached almost 20 years ago in the UK over GSK’s Seroxat paroxetine antidepressant may contravene EU competition law, an advocate general has advised the CJEU.
You may also be interested in...
Teva Will Rebut Latest EU Competition Criticism
In the wake of the European Commission issuing Teva with a supplementary statement of objections over a historical “pay for delay” patent settlement agreement on modafinil with Cephalon, the Israeli firm has insisted on its right to reply.
CJEU Opinion Backs Lundbeck Fine Over Citalopram ‘Pay For Delay’ Deals
A CJEU advocate general has backed a European Commission fine of almost €94m imposed on Lundbeck over “pay for delay” deals struck with four generics firms over citalopram.
CJEU Confirms 'Pay For Delay' Settlements Can Break EU Law
The UK’s Competition and Markets Authority has welcomed an EU Court of Justice ruling that settling patent disputes can break EU law by restricting competition. The case involved so-called "pay for delay" settlements regarding generic competitors to GlaxoSmithKline's antidepressant Seroxat (paroxetine).